News
NVIV
--
0.00%
--
IMS Capital Management Buys Vistra Corp, NVIDIA Corp, Sysco Corp, Sells General Mills Inc, ...
GuruFocus News · 10/07 16:38
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass., September 09, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D.,...
Business Wire · 09/09 12:00
BRIEF-Invivo Says 75% Target Enrollment Achieved For Inspire 2.0 Spinal Cord Injury Study
reuters.com · 09/08 12:22
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury in...
Business Wire · 09/08 12:00
InVivo Therapeutics Reaches 75% of Enrollment Target for Spinal Cord Injury Study
MT Newswires · 09/08 08:48
25 Stocks Moving in Monday's Pre-Market Session
Gainers
Benzinga · 08/23 11:00
Top Premarket Gainers
MT Newswires · 08/20 08:18
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers
Benzinga · 07/29 16:39
BioFlyte Forms Scientific Advisory Board of Prominent Government and Life Science Experts
BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB). The SAB is comprised of seven accomplish...
Business Wire · 07/27 13:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.
Benzinga · 07/26 20:32
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 07/15 11:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Benzinga · 07/14 16:44
InVivo Therapeutics soars 15% on FDA acceptance of preclinical module for HDE submission
The FDA has accepted InVivo Therapeutics' ([[NVIV]] +15.2%) preclinical module, one of three individual modules required for the company’s humanitarian device exemption ((HDE)) application.FDA acceptance indicates that the Agency has
Seekingalpha · 07/13 15:02
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
Benzinga · 07/13 13:13
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 07/13 12:14
InVivo Therapeutics Announces FDA Acceptance Of Preclinical Module In Support OF Company's Complete HDE Submission
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the acceptance by the U.S.
Benzinga · 07/13 12:01
InVivo Therapeutics Preclinical Module for Humanitarian Device Exemption Application Accepted by FDA; Shares Jump
MT Newswires · 07/13 09:50
5 Value Stocks In The Healthcare Sector
What are Value Stocks?
Benzinga · 07/12 14:02
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
CAMBRIDGE, Mass., July 06, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual A...
Business Wire · 07/06 12:05
Webull provides a variety of real-time NVIV stock news. You can receive the latest news about InVivo through multiple platforms. This information may help you make smarter investment decisions.
About NVIV
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.